Summit Therapeutics SMMT Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's shares (diluted)?
- Summit Therapeutics (SMMT) reported shares (diluted) of 775.5M in Q1 2026.
- How has Summit Therapeutics's shares (diluted) changed year-over-year?
- Summit Therapeutics's shares (diluted) increased by 5.1% year-over-year, from 738.1M to 775.5M.
- What is the long-term trend for Summit Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Summit Therapeutics's shares (diluted) has grown at a 64.5% compound annual growth rate (CAGR), from 405.6M to 3B.
- What does shares (diluted) mean?
- The total number of shares that would exist if all potential stock-based instruments were converted into common stock.
- How do you interpret shares (diluted)?
- An increase indicates potential dilution for existing shareholders, while a decrease suggests share buybacks or reduced issuance of equity-based compensation.
- How does shares (diluted) compare across companies?
- Standard across all public companies; investors compare this against historical trends to assess equity dilution risk.